Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Purple Biotech (PPBT)
NASDAQ:PPBT
Holding PPBT?
Track your performance easily
PPBT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.30 - $7.83
Previous Close$2.19
Volume64.79K
Average Volume (3M)99.76K
Market Cap
$4.86M
Enterprise Value-$10.11M
Total Cash (Recent Filing)$15.41M
Total Debt (Recent Filing)$351.00K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Feb 05, 2025EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.94
Shares Outstanding1,413,797
10 Day Avg. Volume48,694
30 Day Avg. Volume99,757
Standard Deviation0.28
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.10
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.23
Forecast
1Y Price Target
$33.00Price Target Upside1104.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Purple Biotech News
PremiumCompany Announcements
Purple Biotech’s Promising Trials and Financial Update
PremiumCompany Announcements
Purple Biotech Unveils Promising Biomarker for Cancer Therapy
PremiumCompany Announcements
Purple Biotech Advances with CAPTN-3 Cancer Platform
PremiumCompany Announcements
Purple Biotech Unveils CAPTN-3 Cancer TherapyBulls Say, Bears Say
Bulls Say
Biomarker AnalysisVarious biomarker analysis on the Phase 2 CM24 trial demonstrates improved overall survival.
Clinical Trial EfficacyThe CM24 experimental arm had consistently greater efficacy for every evaluated endpoint.
Safety And Early ActivityNT219 + cetuximab demonstrated safety and early activity in patients with relapsed/metastatic squamous cell carcinoma of the head & neck, showing dose-proportional PK values.
Bears Say
Clinical Trial ImbalanceThe CM24 + nivolumab + gem/nab-paclitaxel vs gem/nab-paclitaxel cohort was impacted by informative censoring of the control arm which led to an imbalance in the number of patients in the active and control arms.
Resource Requirement For DevelopmentNT219 is Phase 2 ready though company likely needs additional resources to advance this program.
Unsuitable Cohort For AnalysisThe gem/nab-paclitaxel cohort was impacted by informative censoring of the control arm which led to an imbalance in the number of patients in the active and control arms, which made this cohort of patients unsuitable for analysis.
---
Ownership Overview
―
Insiders
8.61% Other Institutional Investors
91.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PPBT FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was $0.30 and its highest was $7.83 in the past 12 months.
What is Purple Biotech’s market cap?
Currently, no data Available
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Feb 05, 2025 which is in 70 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on Nov 15, 2024. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$1.2 by $0.81.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -$0.22.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,835,984 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -$0.39 in its last earnings report, beating expectations of -$1.2. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Purple Biotech?
Among the largest hedge funds holding Purple Biotech’s share is Fisher Asset Management LLC. It holds Purple Biotech’s shares valued at N/A.
---
Purple Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.00 (1104.38% Upside)
$33.00 (1104.38% Upside)
Hedge Fund Trend
Decreased
By 32.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.70%
12-Months-Change
Fundamentals
Return on Equity
-34.28%
Trailing 12-Months
Asset Growth
-22.46%
Trailing 12-Months
Company Description
Purple Biotech
Kitov Pharma Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack in June 2010 and is headquartered in Tel Aviv, Israel.
---
PPBT Stock 12 Month Forecast
Average Price Target
$33.00
▲(1104.38% Upside)
Technical Analysis
Best Analysts Covering PPBT
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+141.27%
reiterated a buy rating 12 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +141.27% per trade.
---